Retrograde cricopharyngeus dysfunction (R-CPD), also known as inability to belch syndrome—a narrative review
Translational Gastroenterology and Hepatology · 2026-05 · 11 · 74-74
DOI: 10.21037/tgh-2025-158 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Translational Gastroenterology and Hepatology, 2026-05. Verfasst von Anders Lehmann und 1 weiteren Autor:innen. Beteiligte Einrichtung: Independent Researcher, Gothenburg, Sweden. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background and Objective: Retrograde cricopharyngeus dysfunction (R-CPD), also known as 'inability to belch syndrome', is an under-recognized disorder wherein the upper esophageal sphincter (UES) fails to open following gaseous reflux. First described in 1987, R-CPD was rediscovered in 2019 along with the first effective treatment, endoscopic botulinum toxin (Botox) injection into the cricopharyngeus (CP). Since then, there has been an explosion of literature on R-CPD. The objectives of this review were to discuss the physiology of belching and R-CPD along with the epidemiology, diagnostic criteria, and clinical experience in managing R-CPD.
Methods
Relevant publications with an abstract in English were identified using the PubMed, Scopus, and Cochrane databases (time frame: 1987-November 15, 2025). Key Content and Findings: Along with an inability to belch, R-CPD is associated with an array of symptoms including gurgling noises in the chest, bloating, flatulence, and chest pain that can compromise a patient's quality of life. The ultimate cause of R-CPD is dysfunction of the vago-vagal reflex mediating UES opening in response to gaseous distention of the esophagus. This can be demonstrated with high-resolution manometry (HRM) by provoking the need to belch with ingestion of a carbonated beverage. However, most R-CPD cases come to light via internet forums such as "#noburpsyndrome" on TikTok and to date most cases (estimated in the thousands) have been treated without physiological confirmation. The reported success rate of Botox treatment is about 90% with only transient dysphagia as a side effect and with many treated patients having a response lasting beyond the expected 4-month duration of action of Botox. This suggests that many R-CPD cases may be amenable to behavioral/biofeedback therapy as has also been claimed on internet forums and in a published case report.
Conclusions
R-CPD is characterized by an inability to belch and a characteristic array of associated symptoms caused by physiological dysfunction of the UES. R-CPD is demonstrable by an HRM study with carbonated beverage provocation and treatable with Botox injection to the CP. Future studies are needed to clarify whether R-CPD exists in a mild-to-severe spectrum and what proportion of R-CPD cases are amenable to behavioral therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Independent Researcher, Gothenburg, Sweden.
- Department of Medicine, Northwestern University's Feinberg School of Medicine, Chicago, IL, USA.
ORCID-Profile: Peter J Kahrilas
Zitieren
APA
Lehmann, A., & Kahrilas, P. J. (2026). Retrograde cricopharyngeus dysfunction (R-CPD), also known as inability to belch syndrome—a narrative review. Translational Gastroenterology and Hepatology, 11, 74-74. https://doi.org/10.21037/tgh-2025-158
Vancouver
Lehmann A, Kahrilas PJ. Retrograde cricopharyngeus dysfunction (R-CPD), also known as inability to belch syndrome—a narrative review. Translational Gastroenterology and Hepatology. 2026;11:74-74. doi:10.21037/tgh-2025-158
BibTeX
@article{Lehmann2026,
author = {Lehmann, Anders and Kahrilas, Peter J},
title = {Retrograde cricopharyngeus dysfunction (R-CPD), also known as inability to belch syndrome—a narrative review},
journal = {Translational Gastroenterology and Hepatology},
year = {2026},
volume = {11},
pages = {74--74},
doi = {10.21037/tgh-2025-158}
}
EUVIMED